Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CU6
vs
S
S&P/ASX 300
Over the past 12 months, CU6 has underperformed S&P/ASX 300, delivering a return of -60% compared to S&P/ASX 300's 2% drop.
Stocks Performance
CU6 vs S&P/ASX 300
Performance Gap
CU6 vs S&P/ASX 300
Performance By Year
CU6 vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals is a radiopharmaceutical company that develops drugs used in medical imaging and cancer treatment. Its main idea is to attach copper-based radioactive isotopes to targeting molecules so doctors can see tumors more clearly on scans or deliver radiation directly to cancer cells. The company does not sell mass-market medicines. It works with hospitals, nuclear medicine specialists, and clinical partners to develop and commercialize diagnostic and therapeutic products, especially for oncology. Its products are designed to be made, shipped, and used through the medical imaging and treatment workflow rather than through regular pharmacy channels. Clarity makes money by advancing these products through development, then selling or licensing approved radiopharmaceuticals and related services into the healthcare market. What makes its business model distinct is its focus on copper radioisotopes, which can be used for both imaging and therapy, giving it a tightly linked product strategy in a specialized part of the drug industry.